Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management.

Recombinant interferon alfa (r-IFN alpha 2) has been shown to normalize the aminotransferase levels in approximately 50% of patients with chronic hepatitis C virus (HCV). Few patients experience a relapse during the treatment, in spite of a complete initial response (breakthrough). We studied 191 HCV Ab-positive patients with histologically proven chronic hepatitis. All of them were treated with r-IFN alpha 2 (3 MU three times a week). A complete response was seen in 54.4%. However, 12 of 104 responders experienced a breakthrough. At the time of breakthrough, neutralizing IFN antibodies were positive in 6 of 12 patients. Binding IFN antibodies were positive in all of these 12 patients. Continued treatment with r-IFN alpha 2, even at higher doses, did not restore the previous response in any patient. All of them were then switched to natural lymphoblastoid IFN, and this rapidly restored a complete response in all of the patients.
AuthorsL Roffi, G C Mels, G Antonelli, G Bellati, F Panizzuti, A Piperno, M Pozzi, D Ravizza, G Angeli, F Dianzani
JournalHepatology (Baltimore, Md.) (Hepatology) Vol. 21 Issue 3 Pg. 645-9 (Mar 1995) ISSN: 0270-9139 [Print] UNITED STATES
PMID7875661 (Publication Type: Journal Article)
Chemical References
  • Antibodies
  • Interferon-alpha
  • Recombinant Proteins
  • Alanine Transaminase
  • Adolescent
  • Adult
  • Aged
  • Alanine Transaminase (blood)
  • Antibodies (analysis)
  • Chronic Disease
  • Female
  • Hepatitis C (blood, epidemiology, therapy)
  • Humans
  • Interferon-alpha (immunology, therapeutic use)
  • Male
  • Middle Aged
  • Prevalence
  • Recombinant Proteins
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: